809 results on '"Calza, Leonardo"'
Search Results
2. Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study
3. Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?
4. Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry.
5. Improvement in insulin sensitivity after switching from an integrase inhibitor‐based regimen to doravirine/tenofovir disoproxil fumarate/lamivudine in people with significant weight gain.
6. Relationship Between Vitamin D Deficiency and Nonalcoholic Fatty Liver Disease in Patients With HIV-1 Infection
7. Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors
8. Efficacy and Safety of Switching to Dolutegravir/Lamivudine in Virologically Suppressed People Living with HIV-1 Aged Over 65 Years
9. COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy
10. Cancer in people with multidrug-resistant HIV.
11. Infectious Diseases and Gender: Focus on HIV Infection
12. Sars-CoV-2 in pregnancy: Why is it better than expected?
13. Development of C-TILDA: A modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1
14. Changes in Serum Inflammatory Markers in Antiretroviral Therapy–Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir
15. Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir
16. Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir/ritonavir
17. Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy
18. Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: A retrospective cohort analysis of data from the PRESTIGIO Registry
19. Doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experience
20. Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting
21. COVID-19 Outcomes in Patients With Uncontrolled HIV-1 Infection
22. Factors associated with hospital admission for COVID-19 in HIV patients
23. No Significant Effect of COVID-19 on Immunological and Virological Parameters in Patients With HIV-1 Infection
24. Simplification to High Genetic Barrier 2-Drug Regimens in People Living With HIV Harboring 4-Class Resistance Enrolled in the PRESTIGIO Registry
25. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)
26. Changes in Serum Inflammatory Markers in Antiretroviral Therapy–Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Tenofovir Alafenamide/Emtricitabine/Bictegravir
27. Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study
28. American Cutaneous Leishmaniasis as a Rare Imported Disease in Europe: A Case Report Favourably Treated with Antimonial Derivatives
29. Ochrobactrum anthropi as an Agent of Nosocomial Septicemia in the Setting of AIDS
30. Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection
31. Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients
32. Additional file 1 of Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?
33. Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patients
34. Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV
35. Prevalence of renal disease within an urban HIV-infected cohort in northern Italy
36. Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients
37. Amiodarone-related pneumonitis and peripheral neuropathy in an elderly patient
38. The Problem of Renal Function Monitoring in Patients Treated With the Novel Antiretroviral Drugs
39. Tenofovir/Emtricitabine/Efavirenz Plus Rosuvastatin Decrease Serum Levels of Inflammatory Markers More Than Antiretroviral Drugs Alone in Antiretroviral Therapy-Naive HIV-Infected Patients
40. Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue
41. Increasing pathomorphism of pulmonary tuberculosis. An observational study of slow clinical, microbiological and imaging response of lung tuberculosis to specific treatment. Which role for linezolid?
42. Short Communication: No Significant Changes in Weight and Body Fat Mass in Suppressed HIV-Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir
43. Short Communication: No Significant Increase in Body Fat Mass in Naive HIV-Infected Patients Starting Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine
44. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients
45. Principi di Malattie Infettive
46. Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients
47. Spontaneous HCV clearance in a patient with HIV infection and a concurrent, never treated, evolutive HCV hepatitis, after over twenty years of chronic co-infection
48. Chronic HCV treatment with peginterferon-ribavirin and severe tuberculosis re-activation
49. SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy?
50. Efavirenz versus nevirapine in current clinical practice: A prospective, open-label observational study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.